Multiplex Assay Market Set to Reach USD 8.84 Billion by 2032 on Escalating Requirement for High Throughput Diagnosis and Precision Medicine – SNS Insider

SNS Insider Unveils Strategic Insights into the U.S. Multiplex Assay Market, while the Region Commands Over 60% Global Share Due to Companion Diagnostics and Biotech R&D Surge.

Austin, June 05, 2025 (GLOBE NEWSWIRE) — Multiplex Assay Market Size & Growth Analysis:

According to SNS Insider, the Multiplex Assay Market was valued at USD 3.05 billion in 2023 and is projected to reach USD 8.84 billion by 2032, growing at a CAGR of 11.24% between 2024 and 2032. North America, particularly the U.S., led the market in 2023 with over 60% share, fueled by rising demand for personalized medicine, increasing FDA approvals for companion diagnostics, and the expanding utility of biomarkers in pharmaceutical and biotech R&D. Multiplex assays offer rapid, high-throughput detection of multiple targets in a single sample, making them invaluable for applications in infectious disease, oncology, and immunology.

Get a Sample Report of Multiplex Assay Market@ https://www.snsinsider.com/sample-request/4486

Market Overview

Multiplex assays have transformed clinical and research diagnostics by allowing simultaneous detection of multiple analytes in a single sample. These assays significantly reduce time and sample requirements while boosting throughput and accuracy. Their adoption is accelerating in disease surveillance, vaccine development, autoimmune disease diagnostics, and oncology. With regulatory backing and a shift towards decentralized diagnostics, multiplex technologies are becoming standard tools in precision healthcare, particularly across developed nations.

Major Players Analysis Listed in this Report are:

• Bio-Rad Laboratories Inc.
• Abcam plc.
• R&D Systems Inc.
• Merck KGaA
• Assay Genie
• Promega Connections
• QIAGEN N.V.
• Thermo Fisher Scientific
• Luminex Corp.
• Perkin Elmer Inc.
• Advanced Cell Diagnostics Inc.
• Seegene Inc.
• other players.

Multiplex Assay Market Report Scope

Report Attributes	Details
Market Size in 2023	US$ 3.05 billion
Market Size by 2032	US$ 8.84 billion
CAGR	CAGR of 11.24% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Regional Analysis	North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)

Segment Analysis

By Product:

In 2023, consumables that include reagents, assay kits, and other disposables were the largest products with a market share of 45%. This prominence is likely due to their frequent inclusion in assay protocols, growing use in routine diagnostic and research applications, as well as an expanding portfolio of run-of-the-mill multiplex testing kits by major manufacturers. Software, meanwhile, is the fastest-growing product category.

By Technology:

Flow cytometry held 40% of the market in 2023. This is largely attributed to its well-proven value in immunophenotyping and cell-based assays in oncology and immunology studies. The advantages of its use in cytokine profiling, as well as its potential for scalability, are some of the main driving factors that make it an attractive option in drug discovery and population-wide studies.

By End-user:

Pharmaceutical and biotechnology companies led the market with a 50% share in 2023, leveraging multiplex assays extensively in biomarker validation, drug target identification, and clinical trial screening. Academic and research institutes, which hold about a 15% share, are anticipated to grow at the fastest rate.

Need Any Customization Research on Multiplex Assay Market, Enquire Now@ https://www.snsinsider.com/enquiry/4486

Multiplex Assay Market Segmentation

By Product

• Consumables
• Instruments
• Software

By Type

• Protein Multiplex Assays
  • Planar Protein Assays
  • Bead-based Protein Assays
• Nucleic Acid Multiplex Assays
  • Planar Protein Assays
  • Bead-based Protein Assays
• Cell-based Multiplex Assays

By Technology

• Flow Cytometry
• Fluorescence Detection
• Luminescence
• Multiplex Real-time PCR
• Other Technologies

By Application

• Research & Development
  • Drug Discovery & Development
  • Biomarker Discovery & Validation
• Clinical Diagnostics
  • Infectious Diseases
  • Cancer
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Nervous System Disorders
  • Metabolism & Endocrinology Disorders
  • Other Diseases

By End-user

• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic laboratories
• Research & Academic Institutes
• Other End-users

Regional Analysis

In 2023, the significant growth in the Multiplex Assay Market is noted to be contributed by North America, especially the United States, holding a share of about 60% of the global market. The existence of major assay developers, established healthcare facilities, and high investments in personal diagnostics support its market. In addition to that, growing FDA approvals and increasing consciousness of multiplex diagnostics for clinical application, the regional market is furthered.

The Asia Pacific is anticipated to register the fastest rate of increase during the forecast period. Fast-paced enhancements in healthcare infrastructure, increasing biotech research investment, and growing prevalence of both chronic and infectious diseases are escalating the requirement for sophisticated diagnostics. China, India, South Korea, among others, are particularly interested in scaling lab capacity and adopting multiplex technologies for research and public health surveillance.

Recent Developments

• In January 2024, the TaqMan Multiplex Assay for quantitative PCR useful, was developed by Thermo Fisher. It allows for the concurrent detection of a variety of targets with high specificity and sensitivity.
• In March 2024, Bio-Rad Laboratories – Bio-Plex Pro Human Cytokine 17-plex Panel, for immunology and cancer research, the next-gen panel enables multi-analyte cytokine detection during a single run.
• In February 2024, Abcam announced a high-throughput solution for FirePlex, allowing high-throughput, multiplexed protein profiling from minimal sample input.

Buy a Single-User PDF of Multiplex Assay Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/4486

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

6. Competitive Landscape

7. Multiplex Assay Market by Product

8. Multiplex Assay Market by Type

9. Multiplex Assay Market by Technology

10. Multiplex Assay Market by Application

11. Multiplex Assay Market by End-user

12. Regional Analysis

13. Company Profiles

14. Use Cases and Best Practices

15. Conclusion

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.